ObsEva (CHIX:OBSNZ) ROCE % : 3,480.07% (As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is ObsEva ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ObsEva's annualized ROCE % for the quarter that ended in Dec. 2022 was 3,480.07%.

ObsEva ROCE % Historical Data

The historical data trend for ObsEva's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva ROCE % Chart

ObsEva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-55.69

-90.97

-116.97

-118.57

-82.69

ObsEva Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROCE %	Get a 7-Day Free Trial															-89.99	-63.63	-242.98	-215.49	3,480.07

ObsEva ROCE % Calculation

ObsEva's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-19.228	/	( ( (59.438 - 21.65)	+	(15.412 - 6.694) )	/ 2 )
	=	-19.228	/	( (37.788	+	8.718)	/ 2 )
	=	-19.228	/	23.253
	=	-82.69 %

ObsEva's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	117.348	/	( ( (16.358 - 18.332)	+	(15.412 - 6.694) )	/ 2 )
	=	117.348	/	( ( -1.974	+	8.718 )	/ 2 )
	=	117.348	/	3.372
	=	3,480.07 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

ObsEva (CHIX:OBSNz) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ObsEva ROCE % Related Terms

Thank you for viewing the detailed overview of ObsEva's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ObsEva (CHIX:OBSNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (CHIX:OBSNz) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228

Website

https://www.obseva.com

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (CHIX:OBSNZ) Headlines

No Headlines